Although the development of BCR::ABL1 tyrosine kinase inhibitors (TKIs) rendered chronic myeloid leukemia (CML) a manageable condition, acquisition of drug resistance during blast phase (BP) progression remains a critical challenge. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.